We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Partnership Formed to Support New Drug Discovery Technology

By Biotechdaily staff writers
Posted on 23 Jul 2008
Artel (Westbrook, ME, USA) and IonGate Biosciences announced a strategic partnership to support the growing application of IonGate's (Frankfurt, Germany) drug discovery technology. More...
The German biotechnology company will leverage Artel's local infrastructure, customer relationships, and market knowledge to increase the exposure and use of its discovery systems and assay development services in North America.

The partnership will focus on IonGate's SURFE2R technology, which enables more effective research involving drug targets such as membrane transporters and ligand-gated ion channels.

Membrane transport proteins play an important role in numerous biologic functions, and they have been linked to cardiac, neurologic, and metabolic disorders; however, these proteins represent a relatively unexplored segment of the drug discovery market. The previous lack of technology for efficient transporter screening has led pharmaceutical companies to focus the majority of their research initiatives on other targets. Ligand-gated ion channel proteins, while more frequently targeted, typically are also subject to less-than-optimal screening methods. IonGate's SURFE2R (SURFace Electrogenic Event Reader) technology represents a significant advance toward more efficient screening of transporters as well as ligand-gated ion channels.

"Transporter-focused drug discovery initiatives are poised for rapid growth worldwide, and the U.S. demand for our SURFE2R technology is rising,” said Dr. Thiemo Gropp Ph.D., Managing Director, IonGate Biosciences, GmbH. "With Artek's support and market expertise, we will be able to deliver the same personalized support to our customers in North America as we deliver to our customers in Europe.”

"We chose Artel because of the company's strong relationships with biopharmaceutical companies, highly skilled staff, and deep understanding of our customers' needs,” said Wolfgang Lerch, president, IonGate Biosciences, Inc. "Our companies' synergistic cultures and strong customer-focused orientations will allow us to bring an unparalleled combination of excellent service and technology to the drug discovery industry.”

IonGate's systems are powerful tools for researchers in large pharmaceutical companies as well as academic environments. The systems are valuable for core essential testing, early-stage screening, ADME (absorption, distribution, metabolism, and excretion) studies, and are able to meet the required throughput. A "label-free therefore of higher value, for a growing array of protein targets. The core of this technology is an electrode biochip that measures the electrical activity of membrane-bound proteins. This activity is observed through measurement of the capacitive charging of the sensor chip by ionic species as they are actively transported across the membrane by the protein targets of interest.

IonGate Biosciences develops, produces, and markets innovative screening technologies to investigate transporters and is the worldwide leader in this new area.

Transporters are essential for the metabolic functions of the cell, data processing in the entire organism, and play a fundamental role in the health of humans. Due to their difficult experimental accessibility, transporters are underrepresented in current drug screening processes. Now, IonGate's original product, SURFE2R One, is joined by the SURFE2R Workstation 500 to provide highly precise functional screening of transporters in the higher-throughput pharmaceutical discovery and development environments. IonGate provides total system solutions, encompassing disposables and reagents, consulting services that include the design of assays and customized applications, and contract laboratory services.

Artel's technology, measurement systems, and value-added services are utilized by life-science laboratories to maximize productivity and ensure quality. The Artel MVS and PCS are very accurate, precise, and easy-to-use systems for achieving data integrity in any process requiring liquid handling and volume measurement. Artel services include liquid handling, quality assurance support and consultation, pipetting technique training and certification for pipette users and laboratory managers, and liquid handler performance verification services for automated laboratories.


Related Links:
Artel
IonGate

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.